Free Trial
→ The investigation Porter spent tens of thousands to document (From Porter & Company) (Ad)tc pixel
NASDAQ:BMRA

Biomerica Q1 2027 Earnings Results & Report

Biomerica logo
$1.59 -0.02 (-1.24%)
Closing price 11/6/2026 03:51 PM Eastern
Extended Trading
$1.60 +0.01 (+0.94%)
As of 11/6/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biomerica beat analyst earnings expectations but missed on revenue in its Q1 2027 results, released October 21, 2026. The company reported EPS of -$0.37 versus the -$1.20 consensus estimate, while revenue of $1.27 million fell short of the $3.63 million estimate by $2.36 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2027
Report Date
Time
After Market Closes

Biomerica EPS Results

Actual EPS
-$0.37
Consensus EPS
-$1.20
Beat/Miss
Beat by +$0.83
One Year Ago EPS
N/A

Biomerica Revenue Results

Actual Revenue
$1.27 million
Expected Revenue
$3.63 million
Beat/Miss
Missed by -$2.36 million
YoY Revenue Growth
N/A

Upcoming Earnings

Biomerica's next earnings date is estimated for Friday, January 8, 2027, based on past reporting schedules.

Conference Call Resources

Biomerica Q1 2027 Earnings FAQ

Biomerica (NASDAQ:BMRA) reported earnings of -$0.37 per share for Q1 2027, beating the consensus estimate of -$1.20. The report was announced on Wednesday, October 21, 2026.

Biomerica reported revenue of $1.27 million for Q1 2027, against a consensus estimate of $3.63 million.

Biomerica's next earnings date is estimated for Friday, January 8, 2027. MarketBeat tracks confirmed and estimated earnings dates for Biomerica on the company's earnings history page.

Biomerica Earnings Headlines

Biomerica Reports First Quarter Fiscal 2027 Financial Results
October 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/16/3382570/0/en/biomerica-reports-first-quarter-fiscal-2027-financial-results.html
Biomerica Announces Board and Governance Committee Transition
October 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/biomerica-announces-board-and-governance-committee-transition?utm_source=marketbeat.com&utm_medium=referral
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
 |  Profits Run (Ad)
Biomerica Files $250 Million Mixed Shelf
September 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/biomerica-files-250-million-mixed-193005577.html
Biomerica Posts Narrower Q4 Loss On Higher Sales; Stock Down
September 2, 2026  |  rttnews.comhttps://www.rttnews.com/3687774/biomerica-posts-narrower-q4-loss-on-higher-sales-stock-down.aspx
Biomerica Reports Fiscal 2026 Fourth-Quarter Sales Growth, Improved Full-Year Loss and Advances in inFoods IBS Commercialization
September 1, 2026  |  quiverquant.comQ
See More Biomerica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biomerica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomerica and other key companies, straight to your email.

About Biomerica

Biomerica (NASDAQ:BMRA) is a medical diagnostics company that develops, manufactures and commercializes products designed to help diagnose and manage gastrointestinal and other health conditions. Its offerings are intended for use by physicians, laboratories and consumers, depending on the product.

The company’s principal product is inFoods IBS, a blood-based diagnostic and therapeutic system designed to identify foods that may contribute to symptoms associated with irritable bowel syndrome. The system is intended to support a personalized dietary program under the direction of a healthcare professional. Biomerica has also developed diagnostic products for gastrointestinal conditions, infectious diseases, food sensitivities and other clinical applications.

Founded in 1971 and headquartered in Irvine, California, Biomerica serves healthcare markets in the United States and internationally through direct sales and distribution relationships. Its products are marketed to healthcare providers, clinical laboratories and other medical channels, with the company focused on expanding the use of diagnostic testing in personalized disease management.

View Biomerica Profile
Earnings Tools